These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 31902939)
1. Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway. Wu CY; Zheng C; Xia EJ; Quan RD; Hu J; Zhang XH; Hao RT Med Sci Monit; 2020 Jan; 26():e919820. PubMed ID: 31902939 [TBL] [Abstract][Full Text] [Related]
2. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β. Zhao WJ; Zhu LL; Yang WQ; Xu SJ; Chen J; Ding XF; Liang Y; Chen G Cancer Sci; 2021 Apr; 112(4):1624-1632. PubMed ID: 33540491 [TBL] [Abstract][Full Text] [Related]
3. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved. Bian P; Hu W; Liu C; Li L Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316 [TBL] [Abstract][Full Text] [Related]
4. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway. Chen L; Zhuo D; Yuan H Immunol Lett; 2022 Jun; 246():10-17. PubMed ID: 35447227 [TBL] [Abstract][Full Text] [Related]
5. Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway. Li J; Jiang L; Liu Z; Li Y; Xu Y; Liu H Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1473-1483. PubMed ID: 32215944 [TBL] [Abstract][Full Text] [Related]
6. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway. Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107 [TBL] [Abstract][Full Text] [Related]
7. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. Bo J; Mao S; Yang J; Wang L; Zheng J; Zhang C; Song M; Chen S; Liu C Phytomedicine; 2024 Sep; 132():155804. PubMed ID: 38943696 [TBL] [Abstract][Full Text] [Related]
8. Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway. Luo X; Wang J; Lu J; Wang X; Miao Y; Li Q; Li X; Wang L Biomed Res Int; 2022; 2022():1874550. PubMed ID: 35757470 [TBL] [Abstract][Full Text] [Related]
10. Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer. Meng L; Zhao P; Hu Z; Ma W; Niu Y; Su J; Zhang Y Anticancer Agents Med Chem; 2022; 22(3):596-602. PubMed ID: 33797387 [TBL] [Abstract][Full Text] [Related]
11. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Ma Y; Qin H; Cui Y Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841 [TBL] [Abstract][Full Text] [Related]
13. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways. Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956 [TBL] [Abstract][Full Text] [Related]
14. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth. Li X; Li Z; Song Y; Liu W; Liu Z Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677 [TBL] [Abstract][Full Text] [Related]
15. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways. Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111 [TBL] [Abstract][Full Text] [Related]
16. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway. Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519 [TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway. Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851 [TBL] [Abstract][Full Text] [Related]
18. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway. Wang SC; Chai DS; Chen CB; Wang ZY; Wang L Biomed Pharmacother; 2015 Oct; 75():33-9. PubMed ID: 26463629 [TBL] [Abstract][Full Text] [Related]
19. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway. Xu J; Cai J; Jin X; Yang J; Shen Q; Ding X; Liang Y Oncol Rep; 2015 Sep; 34(3):1424-30. PubMed ID: 26133772 [TBL] [Abstract][Full Text] [Related]
20. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells. Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]